Genetics research is an important branch of biology. It determines organism's genetic features and genetic processes through genetic DNA, RNA, and so on. Genetics not only makes it possible to find out about the genetic origins and diversity of life, but affects almost every area of medicine, agriculture and ecology.
The importance and potential of genetic research
Sickle cell disease is common worldwide, primarily in Africa, the Mediterranean and the Middle East. A quarter of a million people worldwide are affected by the condition. The disease has a dramatic effect on patients' lives, including frequent medical treatment, low quality of life and diminished life expectancy.
Recombinant proteins are essential components of current biotechnology with applications across all fields of biotech – drug discovery, vaccine development, enzyme engineering, basic biology. But many natural proteins are folding wrong, forming inclusion bodies or unstable when they're expressed in host cells, and therefore have limited activity. So it is essential to choose the right expression system in order to optimise the expression efficiency and performance of recombinant proteins.If you're looking for comprehensive and efficient protein expression solutions, CD Biosynsis offers a top-tier Recombinant Protein Expression service.
The "cell tailors" in the biopharmaceutical workshop are rewriting the history of medicine. Walking into any modern biopharmaceutical company, you can see rows of giant bioreactors, where Chinese hamster ovary cells (CHO cells) are weaving life armor for humans to fight cancer and disease with precision to the nanoscale.
In the arena of biopharmaceutical research and development, recombinant protein technology is undergoing an unprecedented paradigm shift. Once upon a time, there was a saying in the laboratory: "He who gets the protein gets the world", but behind this saying lies the helplessness of many scientific researchers - they have to repeatedly try and make mistakes in the multiple mazes of gene synthesis, cell culture, and protein purification, like explorers holding an incomplete map. A study in a Nature sub-journal in 2018 revealed the scars of the industry: 43% of antibody drug projects worldwide are stuck in the preclinical stage due to insufficient expression, and 28% of candidate molecules fail in the third phase of clinical trials due to abnormal post-translational modifications. These cold numbers are like heavy hammers hitting the nerves of biopharmaceutical people.
In the global competition of biopharmaceutical R&D, the quality of protein expression and purification services has become the core variable that determines the progress of research and the transformation of results. The Nature Biotechnology 2023 industry analysis report pointed out that the annual R&D losses of global biopharmaceutical companies due to technical defects of outsourcing service providers are as high as 4.7 billion US dollars, of which 28.6% of preclinical research delays are directly attributed to technical parameter deviations in the expression and purification process. This data highlights the inevitability of service providers choosing to upgrade from simple technology procurement behavior to strategic decision-making. The current industry technology generation gap is significant: the leading companies have integrated CRISPR-Cas9 gene editing, AI-driven codon optimization algorithms and high-throughput screening platforms, while the tail 20% of suppliers still rely on traditional manual column chromatography processes, and their membrane protein functional activity recovery rate is only 53% of that of the leading companies.
In recombinant protein expression systems, codon optimization has become a key technical means to break through the bottleneck of heterologous gene expression. The biological basis of this strategy stems from the species-specific codon usage bias phenomenon - different organisms have formed unique codon usage frequencies through long-term evolution, and this frequency is significantly positively correlated with the abundance of tRNA pools in host cells. Taking the E. coli expression system as an example, the proportion of arginine codon AGA in its genome (21.3%) far exceeds the CGT codon preferred by mammalian cells (6.8%). This difference directly leads to the occurrence of up to 83% rare codon sites in unoptimized human genes in this system, causing a decrease in ribosome movement rate and accumulation of misfolded proteins.
In the past decade, the discovery of the CRISPR-Cas9 system has completely changed the research paradigm of genetic medicine. This technology, which originates from the bacterial immune mechanism, is like a precise molecular scalpel, bringing hope for the radical cure of single-gene genetic diseases and offering new avenues for treating a wide spectrum of genetic disorders.For more in - depth exploration of CRISPR - based gene - editing technologies, you can visit CRISPR - Based Gene - Editing Services. In the field of Duchenne muscular dystrophy (DMD) treatment, CRISPR-mediated exon reprogramming technology has achieved milestone progress - through the dual AAV vector delivery shear system, 38.2% of patients in the clinical trial (NCT05554276) detected functional dystrophin expression, and muscle biopsy showed a 52% reduction in muscle fiber necrosis area. In the treatment of cystic fibrosis (CF), the combination strategy of CRISPR-Cas12a and base editors successfully repaired the CFTR gene mutation in bronchial organoids, restoring chloride ion transport function to 49.3% of normal levels. This achievement was rated as one of the top ten medical breakthroughs in 2023 by Science magazine.
The CRISPR-Cas9 system is revolutionizing the field of agricultural biotechnology, and its single-base precision editing capability provides a molecular-level solution to food security challenges. The technology achieves trait improvements that are difficult to break through in traditional breeding through targeted genome editing: in the cassava starch synthesis pathway, editing of the GBSSI gene increased tuber yield by 25%; knocking out the rice SD1 gene created a dwarf strain that is resistant to lodging and can withstand a Category 10 typhoon. Field trial data confirm its application potential - wheat TaMLO double-allelic gene-edited lines are 89% resistant to powdery mildew, while soybean FAD2-1A/B site editing increases oleic acid content to 82%. Climate model predictions show that drought-tolerant lines constructed by editing the maize ZmNAC111 gene are expected to stabilize the yield level of 40% of the world's arid areas by 2040. A meta-analysis based on 85 authoritative studies between 2018 and 2023 showed that this technology can shorten the crop improvement cycle by 80%: rice blast-resistant varieties bred using prime editing technology can complete the transformation from laboratory to field in only 3.5 years, which has significant time advantages compared to the more than 15-year cycle required by traditional breeding methods.
In the context of the deep coupling of synthetic biology and gene editing technology, human reproductive genome intervention has broken through the threshold constraints of traditional medical ethics and entered a new stage of fierce competition between technical feasibility and ethical legitimacy. The global laboratory census data published in Nature Biotechnology in 2023 showed that the annual growth rate of experimental projects involving heritable gene modification reached 187%, of which 64% of the research targets were directed at non-disease-related phenotype regulation. This trend of technology application exposed the value orientation shift from basic research to application transformation. Taking the editing of the OCA2 gene (OMIM 611409) as an example, although the P protein encoded by this site has a strong correlation with eye pigment deposition (GWAS P=3.2×10^-28), its functional redundancy assessment has not yet reached a consensus in the academic community. The latest protein interaction network model (STRING v12.0) of the Center for Systems Biology at the University of Cambridge shows that OCA2 has 7 homologous substitution nodes in the melanin synthesis pathway, which fundamentally challenges the ethical defense basis of "gene necessity".
In the millennium-long game between humans and viruses, the emergence of CRISPR-Cas9 technology marks the first time that we have the ability to accurately rewrite the genome of pathogens. Since the engineering application of the CRISPR gene editing system in 2012, this technology derived from the bacterial immune mechanism has completely changed the paradigm of antiviral treatment. For more information on how CRISPR is being applied in gene editing, you can explore CRISPR - Based Gene - Editing Services.
In the wave of rapid development of synthetic biology, the global gene synthesis industry is undergoing unprecedented technological changes. As of 2024, the market size has reached 3.2 billion US dollars, and its growth engine comes from the innovative competition of the three giants GenScript, Integrated DNA Technologies (IDT) and Twist Bioscience. The former has pushed the accuracy of clinical-grade DNA synthesis to 99.999% with its revolutionary error correction algorithm, the middle one has reshaped the scientific research rhythm with 72-hour ultra-fast delivery, and the latter has achieved parallel production of 1.3 million oligonucleotides on a single chip with a silicon-based synthesis platform - this three-dimensional competition of "accuracy, speed, and scale" is rewriting the underlying rules of life science research.
Gene mutations cause systematic errors in protein synthesis by interfering with transcription initiation, splice site recognition, and translation fidelity. The ΔF508 mutation in the CFTR gene causes the loss of phenylalanine in the chloride channel domain, resulting in transmembrane transport dysfunction (cystic fibrosis) in 300,000 patients worldwide. This case confirms the common mechanism of more than 7,000 ClinVar pathogenic variants—80% of rare diseases originate from such molecular cascade disorders. Revealing the precise path from DNA mutation to protein functional defects is a prerequisite for developing CRISPR-mediated precision correction strategies.
When the second hand of the clock ticks once, more than 18 families in the world receive cancer diagnosis notices, and 9 lives are being devoured by the disease. The 2023 monitoring map of the International Agency for Research on Cancer (IARC) reveals that the number of new cancer cases worldwide has exceeded 20.3 million, and the number of deaths is approaching 10 million. This sword of Damocles hanging over the heads of mankind is showing a sharper blade with a growth rate of 15% every decade - the incidence rate may surge by 50% in 2040, and behind this number is the critical point of collapse that countless medical systems are about to face.
Modern biotechnology relies heavily on recombinant protein production because it allows scientists to produce proteins for therapeutic uses as well as industrial and research purposes. Among the various expression systems available the yeast expression system demonstrates exceptional strength and adaptability. Yeast platforms excel in protein production by combining the straightforward nature of prokaryotic systems with eukaryotic capabilities for post-translational modifications. The technology offers useful features along with its distinct set of difficulties. The article thoroughly examines the yeast expression system and assesses its strengths and weaknesses before presenting optimal methods to enhance recombinant protein production.
|
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.